Back to results
US 11,952,373 B2Granted
Method of treating hypercytokinemia by administering the CCR5/CCL5 (RANTES) interaction inhibitor maraviroc
AssigneeIncellDx, Inc.
InventorsEdgar B. Francisco, Hallison Rodrigues, Amruta Pise, Bruce K. Patterson
Life of this patent
Estimating the term…
Abstract
Methods of treating a subject suffering from COVID-19 are provided. Aspects of the methods including administering to the subject an effective amount of an inhibitor of CCR5/CCL5 interaction, such as a CCR5 antagonist. Also provided are methods of assessing severity of a disease involving hypercytokinemia, such as COVID-19, by determining the level of CCL5/RANTES in a subject, as well as compositions for use in such methods.
Claims14
A method of treating a subject for a critical or severe form of a disease involving hypercytokinemia, the method comprising:
- administering to the subject Maraviroc to treat the subject for critical or severe form of the disease involving hypercytokinemia.
Dependencies are inferred from the claim text.